BBC vs. CNCR

Last updated Jun 24, 2026

BBC (Virtus LifeSci Biotech Clinical Trials ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - BBC tracks the LifeSci Biotechnology Clinical Trials Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. Both charge a 0.79% expense ratio.

Performance

BBC vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

BBC

• 1D: 1.59%
• 1M: 13.54%
• YTD: 25.75%
• 6M: 22.73%
• 1Y: 156.95%
• 3Y*: 27.00%
• 5Y*: -0.26%
• 10Y*: 11.15%

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BBC vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
BBC Virtus LifeSci Biotech Clinical Trials ETF	24.72%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

BBC vs. CNCR - Sectors Allocation Comparison

Sectors	BBC	CNCR
Healthcare	100.0%	96.6%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	3.3%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

BBC vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBC

BBC Risk / Return Rank: 95
BBC Sharpe Ratio Rank: 97
BBC Sortino Ratio Rank: 95
BBC Omega Ratio Rank: 91
BBC Calmar Ratio Rank: 97
BBC Martin Ratio Rank: 95

CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBC vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	BBC	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	4.36	—	—
Sortino ratio: Return per unit of downside risk	4.70	—	—
Omega ratio: Gain probability vs. loss probability	1.56	—	—
Calmar ratio: Return relative to maximum drawdown	10.46	—	—
Martin ratio: Return relative to average drawdown	30.65	—	—

Drawdowns

BBC vs. CNCR - Drawdown Comparison

The maximum BBC drawdown since its inception was -76.85%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for BBC and CNCR.

Drawdown Indicators

	BBC	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-76.85%	0.00%	-76.85%
Max Drawdown (1Y) Largest decline over 1 year	-15.10%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-54.45%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-71.97%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-76.85%	—	—
Current Drawdown Current decline from peak	-19.28%	0.00%	-19.28%
Average Drawdown Average peak-to-trough decline	-37.08%	0.00%	-37.08%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.14%	—	—

Volatility

Volatility by Period

	BBC	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.08%	—	—
Volatility (6M) Calculated over the trailing 6-month period	26.79%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	36.27%	0.00%	+36.27%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	39.52%	0.00%	+39.52%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	37.75%	0.00%	+37.75%

BBC vs. CNCR - Expense Ratio Comparison

Both BBC and CNCR have an expense ratio of 0.79%.

Dividends

BBC vs. CNCR - Dividend Comparison

BBC's dividend yield for the trailing twelve months is around 1.35%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BBC Virtus LifeSci Biotech Clinical Trials ETF	1.35%	1.70%	1.00%	0.34%	0.00%	0.00%	0.00%	0.00%	0.00%	2.09%	0.00%	0.51%
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Which ETF is better, BBC or CNCR?

Both ETFs have the same 0.79% expense ratio. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, BBC or CNCR?

BBC and CNCR have the same expense ratio: 0.79% per year.

Which ETF pays a higher dividend yield, BBC or CNCR?

BBC has the higher dividend yield at 1.35%, compared with 0.00% for CNCR.

What is the main difference between BBC and CNCR?

BBC tracks LifeSci Biotechnology Clinical Trials Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: Virtus Investment Partners and Exchange Traded Concepts.